Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
The drugmaker was on its knees when Sir Pascal Soriot took over in 2012. But under his leadership it now does just about everything the UK wants from a business - creating high value-added jobs and developing products that improve people's lives.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.
The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.